Clinical Trial Update: Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception [Phase 3]

View source ↗

Summary

Phase 3 clinical trial of tasimelteon for Non-24-Hour Sleep-Wake Disorder in blind individuals with no light perception has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-24-hour Sleep-wake Disorder

Drugs mentioned

• Hetlioz (tasimelteon)

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Non-24-Hour Sleep-Wake Disorder | Phase 3 | Status: COMPLETED